Search Results 11-20 of 37227 for Two-phase

  1. A Two-part Phase IIb Trial of Vigil in Ewing's Sarcoma - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  2. A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway - Mayo Clinic

    A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway · Overview · Participation eligibility · Participating Mayo Clinic locations.

  3. Phase 2/3 Study Of KPL-387 In Recurrent Pericarditis - Mayo Clinic

    Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines ...

  4. centers-of-excellence

    Overview Tab Title Description Study type Interventional Study phase 2/3 Study IDs Study type Interventional Describes the nature of ...

  5. A Phase 2 Study Of The Safety And Efficacy Of Brepocitinib In Adults With Cutaneous Sarcoidosis (BEACON) - Mayo Clinic

    Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines ...

  6. A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors - Mayo Clinic

    ... Phase 2 dose for evaluation in these patients. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and ...

  7. Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk Myelodysplastic Syndromes - Mayo Clinic

    Phase 2, 80 new subjects will be randomized in a 1:1 ratio into 2 doses/schedules. Participation eligibility. Participant eligibility includes age, gender, type ...

  8. Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS) - Mayo Clinic

    Study ACT16970 consists of 2 parts (A and B) as follows: Part A is a 24 week, double blind, placebo controlled part, preceded by a screening period of up to 4 ...

  9. A Phase 2, Multicenter, Randomized Study of AP26113 - Mayo Clinic

    The purpose of this study is to evaluate the efficacy and safety of two different dosing regimens of AP26113 in patients with anaplastic lymphoma kinase (ALK)- ...

  10. A Phase 2/3 Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab in Subjects With Unresectable or Metastatic Melanoma - Mayo Clinic

    About this study. This is an adaptive clinical trial that includes a dose escalation phase followed by a randomized controlled Phase 3 trial.